Pasithea Therapeutics Corp. (KTTA): Price and Financial Metrics


Pasithea Therapeutics Corp. (KTTA): $0.84

0.01 (+1.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KTTA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

KTTA Stock Price Chart Interactive Chart >

Price chart for KTTA

KTTA Price/Volume Stats

Current price $0.84 52-week high $8.50
Prev. close $0.83 52-week low $0.81
Day low $0.82 Volume 55,800
Day high $0.85 Avg. volume 543,312
50-day MA $1.14 Dividend yield N/A
200-day MA $0.00 Market Cap 19.45M

Pasithea Therapeutics Corp. (KTTA) Company Bio


Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. The company also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. Pasithea Therapeutics Corp. was incorporated in 2020 and is based in Miami Beach, Florida.


KTTA Latest News Stream


Event/Time News Detail
Loading, please wait...

KTTA Latest Social Stream


Loading social stream, please wait...

View Full KTTA Social Stream

Latest KTTA News From Around the Web

Below are the latest news stories about Pasithea Therapeutics Corp that investors may wish to consider to help them evaluate KTTA as an investment opportunity.

Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022

-- Each clinic expected to contribute an estimated USD$5 million (£4 million) annually in revenue -- -- New London locations will provide pharmacy services, ketamine therapy, and other psychiatric treatments, including repeated transcranial magnetic stimulation (“rTMS”) -- MIAMI BEACH, Fla., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments

Yahoo | February 24, 2022

Pasithea Therapeutics Strengthens its Scientific Advisory Board with the Appointment of Preeminent Scientist Dr. Daniel Weinberger

Newest member is a renowned thought leader in the identification of neurobiological mechanisms of mental illnessMIAMI BEACH, Fla., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced the appointment of Dr. Daniel Weinberger to its Scientific Advisory Board (“SAB”). Dr. Weinberger is

Yahoo | February 9, 2022

Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple Sclerosis

Company commences program to develop a tolerizing vaccine and names Hooke Laboratories as its research partnerMIAMI BEACH, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced a new chemical entity (“NCE”) development program and named Massachusetts-based Hooke Laboratories as its res

Yahoo | February 3, 2022

Pasithea Therapeutics Announces Opening of Mental Health Clinic in Los Angeles and Broadens Focus Beyond Ketamine Treatments

In-person clinic will provide ketamine therapy and other novel mental health treatments, including repeated transcranial magnetic stimulation (“rTMS”)MIAMI BEACH, Fla., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that its wholly owned subsidiary, Pasithea Clinics, will open a

Yahoo | January 26, 2022

Casino Stocks: Why LVS, MLCO and WYNN Are Getting Buy-In Today

Casino stocks are on the move today thanks to a recent report out of China's Macau concerning new government regulations.

William White on InvestorPlace | December 23, 2021

Read More 'KTTA' Stories Here

KTTA Price Returns

1-mo -27.59%
3-mo -17.65%
6-mo -80.24%
1-year N/A
3-year N/A
5-year N/A
YTD -52.54%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7058 seconds.